So if BMS are paying $4b to get 35% of Nektar's drug and Merck are paying $450m to get all of vla's (this is Merck's offer less our cash). That means BMS are paying over 25 times what Merck are paying proportionally.
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game